---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 5
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 505
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 505, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning
Your current situation is a classic "false positive" scenario. The executive team sees strong commercial metrics (expansion bookings, shortened cycles), but those are being driven by **sales incentives** (bundle pricing) and **aspirational selling** (roadmap pitches), not necessarily product value.

The most dangerous signal in your data is the behavior of the front-line adjusters: high initial adoption followed by a collapse back to manual notes. This suggests DraftPath is "interesting" but not "useful." When users abandon a tool unless a manager is watching, the product has failed to integrate into the actual workflow; it has merely become a compliance checkbox.

The other options fail to address this core uncertainty:
*   **Scaling Broadly:** This is high-risk. You would be scaling a product that users are already abandoning, potentially baking in churn for next year.
*   **Usage Quality Sprint:** This measures *quantity* of activity (return rates), but your data already shows that usage is being driven by managers rerunning samples for training. More "usage" does not equal more "value."
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. It tells you if people will pay for it without a discount, but it doesn't tell you why the health-liability segment is abandoning it or how to fix the product.
*   **Narrowing to Health-Liability:** This is premature. You don't yet know if the "explainability" issue in health-liability is a systemic product flaw or a specific regulatory hurdle.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move past vanity metrics and support tags to see exactly where the AI fails (overridden vs. rewritten). This tells you if DraftPath is providing a shortcut or creating more work.

### The Trade-off
By choosing the Claim File Review, you are displacing the **Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to scientifically prove whether your current pricing strategy is artificially inflating your growth. You will enter next year without knowing exactly how much of your expansion revenue was "bought" via bundles versus earned via value. You are choosing product-market fit over pricing optimization.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It does not provide the "hard numbers" that a Board of Directors typically prefers during budget locks. While you are digging through files to find the "why," your competitors may be scaling faster, and your Sales team may feel unsupported because you aren't optimizing the commercial engine.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "abandonment" by adjusters was not due to the quality of the suggestions, but due to a lack of internal corporate mandate.

If you found that adjusters *loved* the suggestions but were forbidden from using them by their own internal compliance officers (regardless of whether they could "explain" the action), then DraftPath is a solved technical problem and an unsolved political/commercial problem. In that case, the product isn't broken—the sales and onboarding strategy is.
